4. ASCOupdate 2011, Gastrointestinale Tumore

Diskussionsleiter Dr. D. Helbling, OnkoZentrum Zürich, bespricht folgende Studien:

Abstract 3520: An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM)

Abstract LBA1: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)

Abstract LBA4002: Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial

Abstract 4000: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)

Abstract 4004: A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC)

Abstract 3511: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab

Leave a Reply

Your email address will not be published. Required fields are marked *